ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients

Jiang, Zi-Rong; Yang, Lin-Hui; Jin, Liang-Zi; Yi, Li-Mu; Bing, Ping-Ping; Zhou, Jun*; Yang, Jia-Sheng*广东药学院; 中国医学科学院; 1
Frontiers in Oncology2022-9-20DOI: 10.3389/fonc.2022.988680
25被引8阅读
引用收藏
分享

摘要

BackgroundCuproptosis is a new modality of cell death regulation that is currently considered as a new cancer treatment strategy. Nevertheless, the prognostic predictive value of cuproptosis-related lncRNAs in breast cancer (BC) remains unknown. Using cuproptosis-related lncRNAs, this study aims to predict the immune microenvironment and prognosis of BC patients. and develop new therapeutic strategies that target the disease. MethodsThe Cancer Genome Atlas (TCGA) database provided the RNA-seq data along with the corresponding clinical and prognostic information. Univariate and multivariate Cox regression analyses were performed to acquire lncRNAs associated with cuproptosis to establish predictive features. The Kaplan-Meier method was used to calculate the overall survival rate (OS) in the high-risk and low-risk groups. High risk and low risk gene sets were enriched to explore functional discrepancies among risk teams. The mutation data were analyzed using the "MAFTools" r-package. The ties of predictive characteristics and immune status had been explored by single sample gene set enrichment analysis (ssGSEA). Last, the correlation between predictive features and treatment condition in patients with BC was analyzed. Based on prognostic risk models, we assessed associations between risk subgroups and immune scores and immune checkpoints. In addition, drug responses in at-risk populations were predicted. ResultsWe identified a set of 11 Cuproptosis-Related lncRNAs (GORAB-AS1, AC 079922.2, AL 589765.4, AC 005696.4, Cytor, ZNF 197-AS1, AC 002398.1, AL 451085.3, YTH DF 3-AS1, AC 008771.1, LINC 02446), based on which to construct the risk model. In comparison to the high-risk group, the low-risk patients lived longer (p < 0.001). Moreover, cuproptosis-related lncRNA profiles can independently predict prognosis in BC patients. The AUC values for receiver operating characteristics (ROC) of 1-, 3-, and 5-year risk were 0.849, 0.779, and 0.794, respectively. Patients in the high-risk group had lower OS than those in the low-risk group when they were divided into groups based on various clinicopathological variables. The tumor burden mutations (TMB) correlation analysis showed that high TMB had a worse prognosis than low-TMB, and gene mutations were found to be different in high and low TMB groups, such as PIK3CA (36% versus 32%), SYNE1 (4% versus 6%). Gene enrichment analysis indicated that the differential genes were significantly concentrated in immune-related pathways. The predictive traits were significantly correlated with the immune status of BC patients, according to ssGSEA results. Finally, high-risk patients showed high sensitivity in anti-CD276 immunotherapy and conventional chemotherapeutic drugs such as imatinib, lapatinib, and pazopanib. ConclusionWe successfully constructed of a cuproptosis-related lncRNA signature, which can independently predict the prognosis of BC patients and can be used to estimate OS and clinical treatment outcomes in BRCA patients. It will serve as a foundation for further research into the mechanism of cuproptosis-related lncRNAs in breast cancer, as well as for the development of new markers and therapeutic targets for the disease.

学科与关键词

关键词
cuproptosisbreast cancerlncRNAtumor microenvironmenttumor mutation burden
相关
加载中…
  • A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma
    Yu, Sheng; Tang, Lingxue; Zhang, Qianqian; Li, Wen; Yao, Senbang; Cai, Yinlian; Cheng, Huaidong*HEREDITAS, 2023, 160(1): 31.被引 2
  • The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma
    Zhang, Lishuo; Di, Longjiang; Liu, Jinhui; Lei, Xianli; Gu, Maoli; Zhang, Wenjing*; Wang, Yufu*Frontiers in Genetics, 2023, 14: 1039813.
  • Distinct tumor microenvironment landscapes in gastric cancer classified by cuproptosis-related lncRNAs
    Huang, Jianfeng; Chen, Meixiang; Pei, Wenguang; Xu, Zhijue*; Ning, Jie*; Chen, Changyu*American Journal of Cancer Research, 2022, 13(15): 3687-3700.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-09-20
卷期
第 12 卷
页码
988680
DOI
10.3389/fonc.2022.988680
期刊等级
3区
成果收录
SCIE

作者

  • J

    Jiang, Zi-Rong (第一作者)

    fujian med univ · ningde normal univ

  • Y

    Yang, Lin-Hui

    fujian med univ · ningde normal univ

查看全部 7 位作者收起作者
  • J

    Jin, Liang-Zi

    chinese acad med sci · peking union med coll, inst med biol

  • Y

    Yi, Li-Mu

    1 · guangdong univ pharm

  • B

    Bing, Ping-Ping

    changsha med univ

  • Z

    Zhou, Jun (通讯)

    changsha med univ

  • Y

    Yang, Jia-Sheng (通讯)

    anhui univ technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417